219 related articles for article (PubMed ID: 17151944)
21. Inhibition of brain energy metabolism by the branched-chain amino acids accumulating in maple syrup urine disease.
Ribeiro CA; Sgaravatti AM; Rosa RB; Schuck PF; Grando V; Schmidt AL; Ferreira GC; Perry ML; Dutra-Filho CS; Wajner M
Neurochem Res; 2008 Jan; 33(1):114-24. PubMed ID: 17680360
[TBL] [Abstract][Full Text] [Related]
22. Evidence that the inhibitory effects of guanidinoacetate on the activities of the respiratory chain, Na+,K+-ATPase and creatine kinase can be differentially prevented by taurine and vitamins E and C administration in rat striatum in vivo.
Zugno AI; Scherer EB; Mattos C; Ribeiro CA; Wannmacher CM; Wajner M; Wyse AT
Biochim Biophys Acta; 2007 May; 1772(5):563-9. PubMed ID: 17407807
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of brain energy metabolism by the alpha-keto acids accumulating in maple syrup urine disease.
Sgaravatti AM; Rosa RB; Schuck PF; Ribeiro CA; Wannmacher CM; Wyse AT; Dutra-Filho CS; Wajner M
Biochim Biophys Acta; 2003 Nov; 1639(3):232-8. PubMed ID: 14636955
[TBL] [Abstract][Full Text] [Related]
24. Energy metabolism is compromised in skeletal muscle of rats chronically-treated with glutaric acid.
Ferreira Gda C; Schuck PF; Viegas CM; Tonin A; Latini A; Dutra-Filho CS; Wyse AT; Wannmacher CM; Vargas CR; Wajner M
Metab Brain Dis; 2007 Mar; 22(1):111-23. PubMed ID: 17221303
[TBL] [Abstract][Full Text] [Related]
25. NO scavenging by 3-hydroxyanthranilic acid and 3-hydroxykynurenine: N-nitrosation leads via oxadiazoles to o-quinone diazides.
Backhaus C; Rahman H; Scheffler S; Laatsch H; Hardeland R
Nitric Oxide; 2008 Nov; 19(3):237-44. PubMed ID: 18675929
[TBL] [Abstract][Full Text] [Related]
26. The kynurenines and the seizures.
Guzeva VI; Mikhailov IB; Melnikova NV
Adv Exp Med Biol; 1996; 398():263-4. PubMed ID: 8906274
[No Abstract] [Full Text] [Related]
27. Inhibition of energy production in vitro by glutaric acid in cerebral cortex of young rats.
Silva CG; Silva AR; Ruschel C; Helegda C; Wyse AT; Wannmacher CM; Dutra-Filho CS; Wajner M
Metab Brain Dis; 2000 Jun; 15(2):123-31. PubMed ID: 11092579
[TBL] [Abstract][Full Text] [Related]
28. Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder.
Meier TB; Drevets WC; Wurfel BE; Ford BN; Morris HM; Victor TA; Bodurka J; Teague TK; Dantzer R; Savitz J
Brain Behav Immun; 2016 Mar; 53():39-48. PubMed ID: 26546831
[TBL] [Abstract][Full Text] [Related]
29. Associations between intake of fish and n-3 long-chain polyunsaturated fatty acids and plasma metabolites related to the kynurenine pathway in patients with coronary artery disease.
Karlsson T; Strand E; Dierkes J; Drevon CA; Øyen J; Midttun Ø; Ueland PM; Gudbrandsen OA; Pedersen ER; Nygård O
Eur J Nutr; 2017 Feb; 56(1):261-272. PubMed ID: 26482150
[TBL] [Abstract][Full Text] [Related]
30. Neurochemical evidence that glycine induces bioenergetical dysfunction.
Busanello EN; Moura AP; Viegas CM; Zanatta A; da Costa Ferreira G; Schuck PF; Wajner M
Neurochem Int; 2010 Jul; 56(8):948-54. PubMed ID: 20394787
[TBL] [Abstract][Full Text] [Related]
31. 3-Methylcrotonylglycine disrupts mitochondrial energy homeostasis and inhibits synaptic Na(+),K (+)-ATPase activity in brain of young rats.
Moura AP; Ribeiro CA; Zanatta Â; Busanello EN; Tonin AM; Wajner M
Cell Mol Neurobiol; 2012 Mar; 32(2):297-307. PubMed ID: 21993987
[TBL] [Abstract][Full Text] [Related]
32. Energy metabolism in cortical synaptic terminals from weanling and mature rat brain: evidence for multiple compartments of tricarboxylic acid cycle activity.
McKenna MC; Tildon JT; Stevenson JH; Hopkins IB
Dev Neurosci; 1994; 16(5-6):291-300. PubMed ID: 7768208
[TBL] [Abstract][Full Text] [Related]
33. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
34. Activity of the kynurenine pathway and its interplay with immunity in patients with pulmonary arterial hypertension.
Jasiewicz M; Moniuszko M; Pawlak D; Knapp M; Rusak M; Kazimierczyk R; Musial WJ; Dabrowska M; Kaminski KA
Heart; 2016 Feb; 102(3):230-7. PubMed ID: 26769378
[TBL] [Abstract][Full Text] [Related]
35. Kynurenine pathway metabolism in patients with osteoporosis after 2 years of drug treatment.
Forrest CM; Mackay GM; Oxford L; Stoy N; Stone TW; Darlington LG
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1078-87. PubMed ID: 17042918
[TBL] [Abstract][Full Text] [Related]
36. The uptake of 14C-labeled hydroxyanthranilic acid and enantiomers of tryptophan, kynurenine, and hydroxykynurenine in human blood.
Hankes LV; Schmaeler M
Proc Soc Exp Biol Med; 1975 Sep; 149(4):1063-8. PubMed ID: 1166076
[TBL] [Abstract][Full Text] [Related]
37. Effects of kynurenine metabolites on the electrocorticographic activity in the rat.
Yokoi I; Nishijima Y; Uchida A; Kabuto H; Yamamoto N; Ogawa N
J Neural Transm (Vienna); 1998; 105(2-3):147-60. PubMed ID: 9660093
[TBL] [Abstract][Full Text] [Related]
38. Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: reversal by lactate and pyruvate.
Hodgkins PS; Schwarcz R
Eur J Neurosci; 1998 Jun; 10(6):1986-94. PubMed ID: 9753086
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of creatine kinase activity from rat cerebral cortex by 3-hydroxykynurenine.
Cornelio AR; Rodrigues-Junior Vda S; Rech VC; de Souza Wyse AT; Dutra-Filho CS; Wajner M; Wannmacher CM
Brain Res; 2006 Dec; 1124(1):188-96. PubMed ID: 17097623
[TBL] [Abstract][Full Text] [Related]
40. Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes.
Fujigaki S; Saito K; Takemura M; Fujii H; Wada H; Noma A; Seishima M
Arch Biochem Biophys; 1998 Oct; 358(2):329-35. PubMed ID: 9784247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
